Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for prevention of contrast-induced nephropathy in STEMI
IRCT2014092819316N1Phase 3Completed
- Sponsor
- Vice Chancellor for Research of Mashhad University of Medical Sciences
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pentoxifylline in contrast-induced nephropathy (CIN) and acute ST-segment elevation myocardial infarction (STEMI), sponsored by Vice Chancellor for Research of Mashhad University of Medical Sciences. Started Oct 2013; status: completed.
02
Drugs
pentoxifylline
03
Conditions
contrast-induced nephropathy (CIN)acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on IRCT2014092819316N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2014092819316N1.